Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal

We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics for diseases with high unmet medical needs. Its proprietary TRiM platform enables precise silencing of disease-causing genes, positioning the company as a frontrunner in gene-targeted treatments and one of the best growth stocks in the biotech space.

In July 2025, the company achieved a major milestone, a $100 million payment from Sarepta Therapeutics as part of a broader licensing and collaboration deal. The agreement includes clinical and preclinical RNAi candidates, offering the corporation up to $10 billion in potential milestone and royalty payments. This collaboration provides strong financial backing and external validation of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s RNAi technology.

The business is making significant progress in the late-stage development of its cardiometabolic pipeline. In July 2025, the company initiated the Phase 3 YOSEMITE study for zodasiran in homozygous familial hypercholesterolemia. It also completed enrollment for several Phase 3 trials (SHASTA-3, SHASTA-4, and MUIR-3) evaluating plozasiran for severe hypertriglyceridemia and rare lipid disorders. Plozasiran’s NDA has been accepted by the FDA, with a potential approval date of November 18, 2025.

Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal

A biotechnologist in a lab setting, examining a sample of liquid for research and development.

These developments underscore Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s momentum in bringing RNAi therapies to market. Positive Phase 3 results, including significant reductions in triglycerides and pancreatitis, highlight the strong efficacy of its treatments.

While we acknowledge the risk and potential of ARWR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARWR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.